Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 5, 2014, covering events occurring on November 3, 2014. The filing discloses the entry into a Material Definitive Agreement regarding a settlement with the company's former Chief Executive Officer and President, David Drachman.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed is the settlement obligation:
- Total Settlement Amount: $100,000
- Payment Schedule: $20,000 due within five business days of November 11, 2014, and $80,000 payable in six equal monthly installments thereafter.
Material Changes
The primary material change is the resolution of an arbitration proceeding initiated by Mr. Drachman in January 2014. Under the Settlement Agreement:
- Mr. Drachman waived and released the Company from all claims, including those arising from his Executive Employment Agreement dated September 10, 2013.
- The Company secured a full assignment of all rights, title, claims, and interests Mr. Drachman may have held in a patent application for a combined ablation and recording unit filed on October 22, 2013.
Outlook, Risks, and Contingencies
Contingencies: The settlement is subject to revocation. If Mr. Drachman revokes the agreement on or before November 10, 2014, he is not entitled to any payment, and the Company has no obligation to pay.
Risks: The filing notes that the summary of the agreement is not complete and refers readers to the full text of Exhibit 10.1 for a complete understanding of terms and conditions.
Management Commentary: No forward-looking guidance or management commentary regarding future operations or financial performance is provided in this filing.
Investor Verification Checklist
- Verify the full terms of the Settlement and Mutual Release Agreement in Exhibit 10.1.
- Confirm whether the revocation period (ending November 10, 2014) has passed and if the initial $20,000 payment was executed.
- Assess the strategic value of the assigned patent application for the combined ablation and recording unit.
- Review the company's cash position to ensure it can meet the $80,000 installment obligation over the next six months.